恒瑞医药：两款药物获得临床试验批准

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of SHR-4394 and HRS-3802, both of which are innovative treatments for cancer [1][2][4]. Group 1: Product Development - SHR-4394 is a self-developed injectable biological product intended for the treatment of prostate cancer [2]. - HRS-3802 is a sustained-release tablet that can inhibit tumor cell proliferation and exert anti-tumor effects [3]. - Both products are set to commence clinical trials shortly following the approval [1][2]. Group 2: Market Context - There are currently no similar products approved for market release in both domestic and international markets [4].